Heat shock therapy for castration-resistant prostate cancer
Part of Injuries & trauma clinical trials.
This trial tests a near-infrared whole-body heat shock technique to treat prostate cancer that no longer responds to hormone therapy. It aims to see if this heat-based approach can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer that has stopped responding to hormone therapy (castration-resistant).
- You are between 18 and 89 years old.
- You have a good performance status (able to do daily activities, up to needing some help).
- Your blood tests, liver and kidney function, and heart rhythm are mostly normal.
- You have no other active cancer besides prostate cancer.
- You are willing to follow the study plan and come for regular check-ups.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing if removing the prostate with surgery, after starting hormone therapy, helps men with advanced prostate cancer that has spread to many parts of the body. It aims to see if this approach improves outcomes compared to hormone therapy alone.
This trial tests whether giving intense hormone therapy along with either radiation or surgery can help men with prostate cancer that has spread to a limited number of spots (10 or fewer) but not to organs like the liver or lungs. The goal is to treat both the main tumor and the visible metastatic spots more aggressively.
This trial tests a combination of two experimental drugs, HS-20093 and HRS-5041, for men with advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to see if this new treatment can help control the cancer when other treatments have stopped working.
This trial tests a radioactive treatment (177Lu-PSMA-VG01) that targets a protein called PSMA on prostate cancer cells. It's for men whose cancer has spread and hasn't gotten better with other treatments.
This trial tests whether a short course of high-dose testosterone followed by a radioactive drug (PSMA-617) can help men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to make cancer cells more sensitive to the radiation.
This Phase 1 study tests a new drug that aims to attach to PSMA on prostate cancer cells and activate T-cells (an immune cell type) to attack the cancer. It is for men with advanced prostate cancer that no longer responds to hormone therapy, especially after several prior treatments.
Hear when a new Metastatic Castration-resistant Prostate Cancer (CRPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.